{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:54:37Z","timestamp":1775282077511,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Essential thrombocythaemia (ET) is defined as a myeloproliferative neoplasm with a tendency to haemorrhage and thrombosis. Acute coronary thrombosis can be observed in 1 out of 10 patients. The management of ET patients with acute coronary syndrome (ACS) is a complex clinical condition that requires close follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>Case-1: a 52-year-old female patient with a diagnosis of ET with Janus kinase (JAK)--2 mutation, despite using cytoreductive agents, platelet counts could not be controlled. Platelet counts started to follow a normal course with the ticagrelor treatment given after ACS. Case-2: a 49-year-old female patient who was given ticagrelor treatment after ACS was found to have JAK-2+ ET. The patient whose platelet count returned to normal after ticagrelor treatment was using a cytoreductive agent before the index event. Case-3: a 54-year-old female patient with ET without any genetic mutation. In the patient whose platelet count did not decrease despite ticagrelor treatment and cytoreductive agents given after ACS, platelet counts returned to normal with interferon therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Platelet counts returned to the normal range with ticagrelor treatment given after ACS in patients with JAK+ ET. Monitoring platelet reduction in JAK+ patients with P2Y12 inhibition is thought to be important for new treatment options.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ehjcr\/ytad051","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T10:53:19Z","timestamp":1676371999000},"source":"Crossref","is-referenced-by-count":1,"title":["Can platelet count be controlled with ticagrelor in patients with essential thrombocythaemia? A case series"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-3478","authenticated-orcid":false,"given":"Samet","family":"Y\u0131lmaz","sequence":"first","affiliation":[{"name":"Cardiology Department, Nigde Omer Halisdemir University Research and Training Hospital , A\u015fa\u011f\u0131 Kayaba\u015f\u0131 Mahallesi Hastaneler Cad 51100, Ni\u011fde Merkez, Nigde , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0689-7221","authenticated-orcid":false,"given":"Yakup","family":"\u00c7etinkaya","sequence":"additional","affiliation":[{"name":"Cardiology Department, Nigde Omer Halisdemir University Research and Training Hospital , A\u015fa\u011f\u0131 Kayaba\u015f\u0131 Mahallesi Hastaneler Cad 51100, Ni\u011fde Merkez, Nigde , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-2549","authenticated-orcid":false,"given":"Hasan","family":"Akkaya","sequence":"additional","affiliation":[{"name":"Cardiology Department, Nigde Omer Halisdemir University Medicine Faculty Education and Research Hospital , A\u015fa\u011f\u0131 Kayaba\u015f\u0131 Mahallesi Hastaneler Cad 51100, Ni\u011fde Merkez, Nigde , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0077-1310","authenticated-orcid":false,"given":"Arif","family":"Ar\u0131soy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical Park Hospital , Ye\u015fil\u0131rmak, Vali Zekai G\u00fcm\u00fc\u015fdi\u015f Blv. No: 29, 60230 Tokat Merkez, Tokat , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/blood-2016-05-643346","article-title":"How I treat essential thrombocythemia","volume":"128","author":"Rumi","year":"2016","journal-title":"Blood"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0300-8932(09)71045-0","article-title":"Essential thrombocythemia and acute myocardial infarction","volume":"62","author":"Camacho","year":"2009","journal-title":"Rev Esp Cardiol"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jamacardio.2016.1018","article-title":"Understanding the adverse effects of ticagrelor in practice","volume":"1","author":"Granger","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/ATVBAHA.110.207464","article-title":"Suppressors of cytokine signaling (SOCS) proteins and JAK\/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3","volume":"31","author":"Tamiya","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bjhh.2014.10.001","article-title":"Myeloproliferative neoplasms and the JAK\/STAT signaling pathway: an overview","volume":"37","author":"de Freitas","year":"2015","journal-title":"Rev Bras Hematol Hemoter"},{"key":"2023030116314296200_","first-page":"3","article-title":"The role of Janus Kinase 2 (JAK2) in the pathologenesis of myeloproliferative disorders","volume":"16","author":"Gari","year":"2009","journal-title":"J King Abdulaziz Univ Med Sci"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/ijc.28997","article-title":"Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo","volume":"136","author":"Mezouar","year":"2015","journal-title":"Int J Cancer"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ijc.28947","article-title":"The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer","volume":"136","author":"Gebremeskel","year":"2015","journal-title":"Int J Cancer"},{"key":"2023030116314296200_","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000348413","article-title":"Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study","volume":"130","author":"Chang","year":"2013","journal-title":"Acta Haematol"},{"key":"2023030116314296200_","first-page":"556","article-title":"A rare case of ticagrelor-induced profound isolated thrombocytopenia","volume":"33","author":"Siao","year":"2017","journal-title":"Acta Cardiol Sin"},{"key":"2023030116314296200_","first-page":"73","article-title":"Ticagrelor-associated thrombotic thrombocytopenic purpura","volume":"17","author":"Do\u011fan","year":"2017","journal-title":"Anatol J Cardiol"},{"key":"2023030116314296200_","article-title":"Ticagrelor-induced thrombotic thrombocytopenic purpura: a case report and review of the literature","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"2023030116314296200_","first-page":"1","article-title":"A case report of absolute thrombocytopenia with ticagrelor","volume":"4","author":"Khan","year":"2020","journal-title":"Eur Heart J Case Rep"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytad051\/49174394\/ytad051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/7\/2\/ytad051\/49229532\/ytad051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/7\/2\/ytad051\/49229532\/ytad051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T07:14:12Z","timestamp":1679728452000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytad051\/7035980"}},"subtitle":[],"editor":[{"given":"Silvia","family":"Castelletti","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Georgios A","family":"Christou","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Rafael","family":"Vidal-Perez","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Anas Mohamad","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Rafaella","family":"Siang","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytad051","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2023,2,1]]},"article-number":"ytad051"}}